viru
research
methionin
show
papaverin
compromis
product
virusspecif
protein
infect
cell
without
advers
affect
host
cell
protein
synthesi
treatment
cell
papaverin
strongli
inhibit
product
viral
rna
cellular
rna
dna
found
vsv
caus
immedi
transient
stimul
dna
synthesi
cell
prevent
papaverin
treatment
drug
also
select
block
primari
transcript
vsv
vivo
lesser
extent
vitro
rna
polymeras
activ
virionbound
transcriptas
find
papaverin
strong
inhibitori
effect
viral
biosynthesi
includ
earli
transcript
suggest
vsv
replic
may
depend
host
factor
regul
intracellular
level
cyclic
nucleotid
camp
vesicular
stomat
viru
papaverin
cyclic
amp
phosphodiesteras
inhibitor
rhabdoviru
vesicular
stomat
viru
vsv
unusu
broad
host
rang
may
reflect
part
abil
util
host
regulatori
factor
common
eurkaryot
cell
higher
anim
exampl
recent
shown
inhibitor
cellular
prostaglandin
biosynthesi
prevent
vsv
replic
level
viral
rna
protein
synthesi
mukherje
simpson
simpson
studi
also
demonstr
cell
recov
permiss
state
product
viral
infect
remov
inhibitor
involv
cyclic
nucleotid
modul
replic
anim
virus
report
earlier
exogen
addit
camp
cell
cultur
shown
inhibit
replic
measl
viru
robbin
rapp
recent
demonstr
camp
partial
revers
inhibit
vsv
replic
indomethacin
drug
target
variou
enzym
system
includ
phosphodiesteras
mukherje
simpson
miller
carrigan
show
treatment
neural
cell
papaverin
potent
agonist
phosphodiesteras
elev
intracellular
camp
level
caus
mark
revers
suppress
measl
viru
growth
other
found
rna
protein
synthesi
measl
viru
inhibit
papaverin
neural
nonneur
cell
yoshikawa
yamanouchi
commun
shown
papaverin
prevent
viral
rna
protein
synthesi
cell
infect
vsv
act
earli
stage
viral
growth
cycl
indiana
strain
vsv
grown
cultur
cell
prepar
work
stock
mukherje
simpson
cultur
cell
use
studi
maintain
reinforc
mem
rmem
supplement
newborn
calf
serum
nc
infect
titrat
perform
plaqu
assay
monolay
cultur
describ
earlier
simpson
et
al
viru
use
primari
transcript
assay
label
rna
growth
h
cell
uridin
specif
activ
cimmol
pciml
purifi
establish
method
bean
simpson
method
baltimor
et
al
determin
primari
transcript
vivo
method
bean
simpson
use
minor
chang
cell
monolay
x
cell
infect
purifi
vsv
input
approxim
x
cpm
x
pfu
per
mm
petri
dish
cultur
determin
viral
protein
synthesi
cell
infect
vsv
pulselabel
methionin
differ
regimen
drug
treatment
describ
figur
legend
wash
cell
lyse
laemmli
buffer
trishcl
ph
sdslo
glycerol
sonic
min
combin
pmercaptoethanol
bromphenol
blue
boil
min
dissoci
protein
analyz
standard
discontinu
sdspage
acrylamid
resolv
gel
laemmli
protein
detect
autoradiographi
use
kodak
xray
film
expos
cronex
lightningplu
intensifi
screen
day
analysi
viral
rna
infect
cell
pulselabel
inorgan
p
phosphat
phosphatefre
rmem
differ
time
infect
accord
drug
regimen
describ
result
total
rna
extract
wash
monolay
solubil
ste
buffer
contain
sd
lysat
aspir
three
time
gaug
needl
rna
extract
stesatur
phenol
precipit
ethanol
bean
simpson
rna
prepar
dissolv
ste
buffer
urea
glycerol
store
analyz
agaros
acidurea
slab
gel
method
lynch
et
al
autoradiographi
gel
fix
methanol
expos
kodak
film
cronex
lightningplu
intensifi
screen
day
preliminari
experi
carri
establish
condit
maximum
inhibit
vsv
growth
papaverin
cell
although
papaverin
recent
shown
inhibit
measl
viru
replic
neural
cell
cultur
treat
dose
level
fm
day
miller
carrigan
found
cell
requir
exposur
pm
papaverin
infect
obtain
reduct
viru
yield
tabl
use
lower
dose
omit
drug
infect
less
effect
reduc
viru
yield
prolong
drug
treatment
cell
day
produc
cytotox
effect
subsequ
experi
cell
treat
drug
concentr
pm
period
exceed
h
revers
drug
effect
investig
pretreat
cell
papaverin
infect
viru
incub
cell
h
remov
drug
condit
rapid
progress
recoveri
viral
permiss
state
increas
viru
yield
seen
function
time
drug
remov
tabl
kinet
viru
product
cell
recoveri
period
similar
group
untreat
cultur
infect
time
h
pi
papaverin
remov
test
cultur
indic
viral
shown
also
test
effect
known
modul
cyclic
nucleotid
metabol
abil
counteract
viral
inhibitori
effect
papaverin
signific
effect
obtain
cell
expos
cgmp
treatment
drug
tabl
cyclic
gmp
total
negat
papaverin
block
viral
replic
present
entir
drug
treatment
period
inhibit
measl
viru
growth
vitro
papaverin
similarli
antagon
exogen
addit
cgmp
miller
carrigan
although
papaverin
known
affect
intracellular
level
ion
turn
regul
phosphodiesteras
activ
carpendo
et
al
found
alter
calcium
concentr
cultur
medium
appar
effect
inhibit
vsv
drug
data
shown
determin
effect
drug
viral
protein
synthesi
papaverinetr
cell
pulselabel
methionin
infect
total
radiolabel
protein
analyz
sdspage
gel
illustr
fig
product
viral
protein
total
block
cell
infect
immedi
drug
treatment
fig
lane
even
though
cellular
protein
synthesi
appar
reduc
cf
fig
lane
condit
employ
experi
papaverin
reduc
yield
infecti
viru
infect
control
cultur
data
shown
calcium
spare
effect
inhibit
viral
protein
synthesi
drug
fig
lane
product
process
viral
mrna
might
impair
papaverinetr
cell
analyz
rna
speci
produc
earli
stage
infect
none
expect
vsv
mrna
genomelength
rna
detect
fig
synthesi
cellular
ribosom
rna
also
prevent
drug
fig
lane
effect
papaverin
host
dna
synthesi
also
examin
fig
illustr
hlthymidin
uptak
drugtreat
cell
total
block
whether
infect
interest
asid
experi
find
immedi
infect
vsv
appreci
stimul
thymidin
incorpor
comparison
uninfect
cell
fig
although
true
signific
phenomenon
unknown
appear
relat
viru
uptak
sinc
multipl
depend
occur
fig
gel
electrophoresi
rna
speci
synthes
ceil
treat
papaverin
infect
vsv
cell
pretreat
papaverin
pm
h
infect
vsv
pfucel
incub
fresh
medium
contain
drug
label
pciml
h
pi
total
rna
extract
analyz
acidurea
agaros
gel
materi
method
rna
speci
untreat
viru
infect
cell
lane
infect
cell
treat
papaverin
lane
mocktreat
uninfect
cell
lane
uninfect
cell
treat
papaverin
lane
arrow
indic
posit
ribosom
rna
respect
infect
cell
incub
cold
data
shown
collect
forego
experi
establish
papaverin
block
host
nucleic
acid
synthesi
protein
synthesi
condit
vsvcode
polypeptid
rna
speci
produc
absenc
viral
mrna
synthesi
interest
determin
whether
papaverin
directli
affect
viral
transcript
test
primari
transcript
vivo
drugtreat
cell
measur
associ
radiolabel
input
viral
genom
rna
rnase
resist
complex
first
h
infect
see
materi
method
fig
show
primari
transcript
vsv
ceil
w
incubantim
time
platen
evan
simpson
thymidin
uptak
shown
function
time
pulselabel
follow
viru
adsorpt
drugtreat
infect
cell
drugtreat
uninfect
cell
mocktreat
infect
cell
mocktreat
uninfect
cell
fig
effect
papaverin
primari
transcript
vesicular
stomat
viru
monolay
cultur
cell
cultur
expos
rmem
nc
without
pm
papaverin
h
drug
treat
cultur
temperatur
equilibr
inocul
gradientpurifi
vsv
radiolabel
rna
h
viru
input
approxim
pfu
per
ceil
x
cpm
cell
wash
cold
bss
viru
adsorpt
incub
prewarm
serumfre
medium
contain
lack
papaverin
pm
individu
cultur
extract
total
rna
differ
time
interv
percentag
ribonucleas
resist
radioact
anneal
determin
materi
method
percent
rnaseresist
count
function
time
incub
untreat
infect
cultur
cultur
treat
infect
drug
treat
papaverin
infect
larg
prevent
earli
stage
infect
determin
whether
impair
primari
transcript
seen
experi
might
involv
direct
action
drug
viral
transcript
complex
test
activ
virion
transcriptas
vitro
reaction
mixtur
contain
differ
concentr
papaverin
shown
tabl
transcriptas
activ
incomplet
inhibit
reaction
mixtur
drug
concentr
pm
higher
consid
drug
level
greater
pm
toxic
cell
use
studi
partial
inhibit
vitro
viral
transcriptas
activ
obtain
suggest
stronger
block
vsv
transcript
induc
vivo
may
necessarili
reflect
direct
effect
papaverin
viral
transcript
complex
condit
use
use
papaverin
studi
revers
inhibitor
viral
replic
implic
particip
endogen
host
factor
biosynthet
activ
vesicular
stomat
viru
infect
permiss
cell
pharmacolog
papaverin
alkaloid
deriv
papav
poppi
act
smooth
muscl
relax
inhibit
phosphodiesteras
caus
increas
intracellular
level
cyclic
amp
triner
et
al
carpendo
et
al
recent
studi
possibl
role
cyclic
nucleotid
modul
acut
persist
infect
measl
viru
establish
elev
camp
level
either
exogen
addit
nucleotid
robbin
rapp
treatment
cell
papaverin
miller
carrigan
yoshikawa
yamanouchi
render
cell
revers
nonpermiss
measl
viru
replic
yoshikawa
yamanouchi
report
papaverin
block
measl
viru
vitro
level
viral
rna
synthesi
although
abil
detect
rel
low
level
measl
p
protein
neural
nonneur
cell
treat
drug
would
indic
inhibit
viral
transcript
system
absolut
worker
shown
papaverin
select
inhibit
product
intracellular
matrix
protein
measl
infect
neural
cell
without
neg
affect
synthesi
viral
structur
protein
detect
immunofluoresc
stain
miller
carrigan
would
thu
appear
host
cell
differ
influenc
extent
papaverin
interfer
virusspecif
macromolecular
synthesi
observ
system
